What's in NeuroRx, Inc.'s pipeline?

NeuroRx, Inc. has 3 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with NeuroRx, Inc.'s portfolio?

Top competitors by shared drug class: Acacia Pharma Ltd, Alexza Pharmaceuticals, Inc., Alkermes, Inc., All India Institute of Medical Sciences, Bhubaneswar, AstraZeneca.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/neurorx-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

NeuroRx, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NeuroRx, Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
NRX-101 Oral Capsule	NRX-101 Oral Capsule	phase 3	Fixed-dose combination (NMDA receptor modulator + atypical antipsychotic)	NMDA receptor (d-cycloserine component); dopamine D2 receptor and serotonin 5-HT7 receptor (lurasidone component)	Psychiatry / Neurology
Lurasidone Oral Capsule	Lurasidone Oral Capsule	phase 3	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT7 receptor, Serotonin 5-HT1A receptor	Psychiatry/Neurology

Therapeutic area mix

Psychiatry / Neurology · 1
Psychiatry/Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Acacia Pharma Ltd · 1 shared drug class
Alexza Pharmaceuticals, Inc. · 1 shared drug class
Alkermes, Inc. · 1 shared drug class
All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
AstraZeneca · 1 shared drug class
Benaroya Research Institute · 1 shared drug class
BioXcel Therapeutics Inc · 1 shared drug class
AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for NeuroRx, Inc.:

Cite this brief

Drug Landscape (2026). NeuroRx, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/neurorx-inc. Accessed 2026-06-10.